Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd ADR (NY: CANF )

2.650 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.650
Bid (Size) 2.440 (1)
Ask (Size) 2.650 (4)
Prev. Close 2.650
Today's Range 2.650 - 2.650
52wk Range 0.5400 - 6.860
Shares Outstanding 515,746,293
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
From Can-Fite BioPharma Ltd.
Via Business Wire

Performance

YTD
+348.00%
+348.00%
1 Month
-7.67%
-7.67%
3 Month
-17.19%
-17.19%
6 Month
+20.45%
+20.45%
1 Year
+263.05%
+263.05%

More News

Read More
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
From Can-Fite BioPharma Ltd.
Via Business Wire
Recap: Can Fite Biofarma Q1 Earnings
Via Benzinga
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Via MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know
Via Benzinga
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.